Literature DB >> 23527721

Effectiveness of fibrin sealant after cementless total hip replacement: a double-blind randomized controlled trial.

F Randelli1, L Banci, V Ragone, M Pavesi, G Randelli.   

Abstract

UNLABELLED: Fibrinogen-based sealants have been used to improve hemostasis after total hip replacement (THR) with conflicting results. We therefore conducted a double-blind randomized controlled trial to determine whether the commercially available fibrin sealant Quixil is effective in reducing the volume of red blood cell transfusions, postoperative blood loss and postoperative hemoglobin drop. Patients with coxarthrosis scheduled for primary cementless THR, were enrolled in a single hospital setting and randomized to either a fibrin sealant group (n=35) or a negative control group (n=35). The surgeon was blind to group allocation until the moment of fibrin application, while the cardiologist determining the need for transfusions remained blind throughout the intervention. In the fibrin sealant group, less blood was lost in the first 48 hours (median, 125 vs 200 ml), fewer patients required allogeneic blood transfusion (1 vs 6 in the control group), and fewer total units of allogeneic blood were transfused (2 vs 12). These differences, however, were not significant partly due to confounding from the use of autologous transfusion of predeposited blood (according to a more liberal regime) and intraoperative autologous blood reinfusion in some patients of both groups. Excluding these last individuals from analysis, no remaining patient of the fibrin sealant group had an allogeneic blood transfusion that, instead, was carried out on 5 patients (23.8 percent) of the control group (p=0.048). Overall postoperative hemoglobin drop from baseline was significantly less in the fibrin-treated group on day 7 (mean, 3.5 vs 4.5 g/dl; p=0.02). No adverse events were associated with fibrin treatment. These results strengthen the evidence in support of the safety and efficacy of the use of fibrin sealant in improving hemostasis after THR. CLINICAL TRIAL REGISTRATION: EudraCT 2008-002024-28.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23527721     DOI: 10.1177/039463201302600118

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  7 in total

1.  Comparative analysis of autologous blood transfusion and allogeneic blood transfusion in surgical patients.

Authors:  Miao-Yun Long; Zhong-Han Liu; Jian-Guang Zhu
Journal:  Int J Clin Exp Med       Date:  2014-09-15

2.  Tranexamic acid versus fibrin sealant in primary total hip replacement: a comparative study.

Authors:  Aatif Mahmood; Seif Sawalha; Aaron Borbora; Gunasekaran Kumar; Viju Peter
Journal:  Eur J Orthop Surg Traumatol       Date:  2017-01-25

3.  Prevention of postoperative anemia in hip hemiarthroplasty for femoral neck fractures: comparison between local haemostatic agents.

Authors:  Antonio Ziranu; Cesare Meschini; Davide De Marco; Giuseppe Sircana; Maria Serena Oliva; Giusepp Rovere; Andrea Corbingi; Raffaele Vitiello; Giulio Maccauro; Enrico Pola
Journal:  Orthop Rev (Pavia)       Date:  2022-10-13

4.  Outcomes of total hip arthroplasty in patients with primary immune thrombocytopenia.

Authors:  Seung-Jae Lim; Ingwon Yeo; Chan-Woo Park; Young-Wan Moon; Youn-Soo Park
Journal:  BMC Musculoskelet Disord       Date:  2015-10-05       Impact factor: 2.362

5.  The Efficacy of Bipolar Sealer on Blood Loss in Primary Total Hip Arthroplasty: A Meta-Analysis.

Authors:  Ji-Kang Min; Qiang-Hua Zhang; Hai-Dong Li; Heng Li; Pan Guo
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

Review 6.  A Systematic Review and Meta-analysis of the Topical Administration of Fibrin Sealant in Total Hip Arthroplasty.

Authors:  Zhihu Zhao; Xinlong Ma; Jianxiong Ma; Xiaolei Sun; Fengbo Li; Jianwei Lv
Journal:  Sci Rep       Date:  2018-01-08       Impact factor: 4.379

7.  Stress shielding effects of two prosthetic groups after total hip joint simulation replacement.

Authors:  Chengdong Piao; Dankai Wu; Min Luo; Hongshun Ma
Journal:  J Orthop Surg Res       Date:  2014-08-30       Impact factor: 2.359

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.